<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02435901</url>
  </required_header>
  <id_info>
    <org_study_id>08057</org_study_id>
    <nct_id>NCT02435901</nct_id>
  </id_info>
  <brief_title>HSCT For Patients With High Risk Hemoglobinopathies Using Reduced Intensity</brief_title>
  <official_title>ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT) IN PATIENTS WITH HIGH RISK HEMOGLOBINOPATHIES LIKE SICKLE CELL DISEASE AND β-THALESSEMIA-MAJOR USING REDUCED INTENSITY CONDITIONING REGIMEN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the use of reduced intensity conditioning regimen in patients with&#xD;
      high risk hemoglobinopathy Sickle Cell and B-Thalassemia Major in combination with standard&#xD;
      immunosuppressive medications, followed by a routine stem cell transplant in order to assess&#xD;
      whether or not it is as effective as myeloablative high dose chemotherapy and transplant.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Standard myeloablative regimens are toxic to non-hematopoietic tissue and are associated with&#xD;
      treatment related mortality and morbidity (TRM). Preparative regimens that are not&#xD;
      myeloablative are associated with a greatly decreased incidence of TRM. In addition to&#xD;
      providing a less toxic regimen, the reduced intensity chemotherapy preparative regimen also&#xD;
      remains immunosuppressive enough to allow donor engraftment. Recent report of&#xD;
      non-myeloablative regimens which resulted in engraftment of allogeneic stem cell in&#xD;
      hematological malignancies raises the possibility that this conditioning regimen might be&#xD;
      useful in achieving engraftment in non hematological disorder.&#xD;
&#xD;
      In an effort to achieve stable engraftment with any suitable donor stem cell source and to&#xD;
      minimize toxicity the investigators have developed a new reduced intensity conditioning&#xD;
      regimen for high risk hemoglobinopathies with the main aim of significantly suppressing the&#xD;
      recipient's immune system and facilitate engraftment.&#xD;
&#xD;
      Non-myeloablative or reduced-intensity immunosuppressive preparative regimens have achieved a&#xD;
      stable, mixed chimerism engraftment and successful allogeneic bone marrow transplants.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2008</start_date>
  <completion_date type="Actual">December 2019</completion_date>
  <primary_completion_date type="Actual">March 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Sustained Cell Engraftment of Donor Cells</measure>
    <time_frame>1 year</time_frame>
    <description>Sustained stem cell engraftment of donor cells will be evaluated by chimerism (FISH fluorescence in situ hybridization OR VNTR (Variable Number of Tandem Repeats), based on recipient/donor gender, at 30 days, 100 days, 6 months and 1 year following the use of reduced intensity conditioning.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Treatment Related Mortality and Morbidity</measure>
    <time_frame>2 years</time_frame>
    <description>Patients will be evaluated for incidence and severity of graft versus host disease, infection, and cardiopulmonary complications.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival; Number of Participants Who Survived at 2 Years</measure>
    <time_frame>2 years</time_frame>
    <description>29 participants will be evaluated for Event Free Survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">29</enrollment>
  <condition>Sickle Cell Disease</condition>
  <condition>Beta Thalassemia-Major</condition>
  <arm_group>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alemtuzumab (Campath IH)</intervention_name>
    <description>Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
    <other_name>Campath-IH</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Melphalan</intervention_name>
    <description>Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine</intervention_name>
    <description>Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mycophenolate mofetil</intervention_name>
    <description>Immunosuppressant to prevent graft vs host disease is given on Day -1.</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>Immunosuppressant to prevent graft vs host disease is given Day -1 prior to stem cell infusion</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.</description>
    <arm_group_label>Reduced Intensity Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient Inclusion Criteria for Sickle Cell Disease&#xD;
&#xD;
          -  Patients at least one year of age to less than or equal to 21 years of age with&#xD;
             (Sickle Cell Disease-SS or Sickle Cell-S-β-Thalassemia and with one or more of the&#xD;
             following disease complications:&#xD;
&#xD;
          -  Development of stroke on chronic transfusion protocol.&#xD;
&#xD;
          -  Allosensitization on chronic transfusion therapy&#xD;
&#xD;
          -  Impaired neuropsychological function and abnormal MRI scan&#xD;
&#xD;
          -  Abnormal Transcranial Doppler studies&#xD;
&#xD;
          -  Acute chest syndrome (2 to 3 episodes of acute chest syndrome in last 3 to 4 years).&#xD;
&#xD;
          -  Ferritin level &lt; 1500 mg/ml&#xD;
&#xD;
          -  Recurrent painful priapism; 3-4 episodes/year requiring intervention.&#xD;
&#xD;
          -  Recurrent vaso-occlusive crisis of at least 3 to 4 episodes/year.&#xD;
&#xD;
          -  Osteonecrosis of multiple bones with documented destructive changes.&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Patients physically and psychologically capable of undergoing transplantation and a&#xD;
             period of strict isolation.&#xD;
&#xD;
          -  Ferritin &lt; 1500&#xD;
&#xD;
          -  Liver Iron Concentration &lt; 6mg/g&#xD;
&#xD;
        Patient Inclusion Criteria for β Thalassemia major Patients less than or equal to 21 years&#xD;
        of age with B- Thalassemia major on routine monthly transfusion protocol or with one or&#xD;
        more of the following complications;&#xD;
&#xD;
          1. Hepatomegaly.&#xD;
&#xD;
          2. Liver biopsy revealing evidence of portal fibrosis as A) Mild B) Moderate&#xD;
&#xD;
          3. Ferritin level≤ 1500ng/ml&#xD;
&#xD;
          4. Liver Iron Concentration (LIC) &lt; 6mg/g&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Exclusion Criteria for Both Sickle Cell and β Thalassemia Major Patient&#xD;
&#xD;
          -  HIV positive result confirmed by Western Blot.&#xD;
&#xD;
          -  Pregnancy (Pregnancy testing for females of child-bearing age will be performed and&#xD;
             those with a positive serum β-Human Chorionic Gonadotropin will be excluded) and&#xD;
             lactating females.&#xD;
&#xD;
          -  Creatinine greater than two times the upper limit of normal for the laboratory,&#xD;
&#xD;
          -  Pulmonary disease with FVC, FEV1 or DLCO parameters &lt; 50% predicted (corrected for&#xD;
             hemoglobin) or stage 3 or 4 sickle lung disease.&#xD;
&#xD;
          -  Cardiac insufficiency or coronary artery disease requiring treatment&#xD;
&#xD;
          -  Active infection requiring systemic antibiotic therapy with antibacterial, antifungal&#xD;
             or antiviral agents&#xD;
&#xD;
          -  Lansky performance score &lt;70%- (Appendix B)&#xD;
&#xD;
          -  Acute hepatitis/biopsy evidence of cirrhosis.&#xD;
&#xD;
          -  Pulmonary Hypertension&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>21 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Cohen Children's Medical Center of New York</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>April 24, 2015</study_first_submitted>
  <study_first_submitted_qc>May 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2015</study_first_posted>
  <results_first_submitted>December 11, 2019</results_first_submitted>
  <results_first_submitted_qc>October 13, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">November 5, 2020</results_first_posted>
  <last_update_submitted>July 30, 2021</last_update_submitted>
  <last_update_submitted_qc>July 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Reduced Intensity Conditioning Regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
    <mesh_term>Thalassemia</mesh_term>
    <mesh_term>beta-Thalassemia</mesh_term>
    <mesh_term>Hemoglobinopathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Alemtuzumab</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Outcome data to include study findings.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 14, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/01/NCT02435901/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>There were no significant events in the study which prevented participant enrollment.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Reduced Intensity Regimen</title>
          <description>Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused&#xD;
alemtuzumab (Campath IH): Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17&#xD;
Fludarabine: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.&#xD;
Melphalan: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.&#xD;
Cyclosporine: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to s</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Reduced Intensity Regimen</title>
          <description>Administration of reduced doses of alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. On Day -1 Cyclosporine OR Tacrolimus will be initiated along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the Human Leukocyte Antigen (HLA) matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.&#xD;
alemtuzumab (Campath IH): Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17&#xD;
Fludarabine: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.&#xD;
Melphalan: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.&#xD;
Cyclosporine: Immunosuppressant to prevent graft vs host disease is given on Day -1</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="29"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Hemoglobinopathies</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Sustained Cell Engraftment of Donor Cells</title>
        <description>Sustained stem cell engraftment of donor cells will be evaluated by chimerism (FISH fluorescence in situ hybridization OR VNTR (Variable Number of Tandem Repeats), based on recipient/donor gender, at 30 days, 100 days, 6 months and 1 year following the use of reduced intensity conditioning.</description>
        <time_frame>1 year</time_frame>
        <population>All 29 participants were analyzed at time-points of 30 days, 100 days, 6 month and 1 year for sustained stem cell engraftment of donor cells.</population>
        <group_list>
          <group group_id="O1">
            <title>Reduced Intensity Regimen</title>
            <description>Alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. Day -1 Cyclosporine OR Tacrolimus along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the HLA matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.&#xD;
alemtuzumab (Campath IH): Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17&#xD;
Fludarabine: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.&#xD;
Melphalan: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.&#xD;
Cyclosporine: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to s</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Sustained Cell Engraftment of Donor Cells</title>
          <description>Sustained stem cell engraftment of donor cells will be evaluated by chimerism (FISH fluorescence in situ hybridization OR VNTR (Variable Number of Tandem Repeats), based on recipient/donor gender, at 30 days, 100 days, 6 months and 1 year following the use of reduced intensity conditioning.</description>
          <population>All 29 participants were analyzed at time-points of 30 days, 100 days, 6 month and 1 year for sustained stem cell engraftment of donor cells.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Treatment Related Mortality and Morbidity</title>
        <description>Patients will be evaluated for incidence and severity of graft versus host disease, infection, and cardiopulmonary complications.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Intensity Regimen</title>
            <description>Alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. Day -1 Cyclosporine OR Tacrolimus along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the HLA matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.&#xD;
alemtuzumab (Campath IH): Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17&#xD;
Fludarabine: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.&#xD;
Melphalan: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.&#xD;
Cyclosporine: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to s</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Treatment Related Mortality and Morbidity</title>
          <description>Patients will be evaluated for incidence and severity of graft versus host disease, infection, and cardiopulmonary complications.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Grade I-Grade III GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No complications</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Event Free Survival; Number of Participants Who Survived at 2 Years</title>
        <description>29 participants will be evaluated for Event Free Survival.</description>
        <time_frame>2 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Reduced Intensity Regimen</title>
            <description>Alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. Day -1 Cyclosporine OR Tacrolimus along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. On Day 0 the HLA matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.&#xD;
alemtuzumab (Campath IH): Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17&#xD;
Fludarabine: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.&#xD;
Melphalan: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.&#xD;
Cyclosporine: Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to s</description>
          </group>
        </group_list>
        <measure>
          <title>Event Free Survival; Number of Participants Who Survived at 2 Years</title>
          <description>29 participants will be evaluated for Event Free Survival.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="29"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Expired Secondary to Sepsis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Expired Secondary to GVHD</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Survived Participants</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data was collected up to the end of the first year post transplant.</time_frame>
      <desc>Serious adverse events included 3 participants who expired within the first year post transplant. One participant expired secondary to sepsis episode. Two participants expired secondary to complications of Grade III-IV graft vs. host disease.&#xD;
Adverse event included13 patients experienced adverse event of Grade I-II graft vs host disease, and responded to oral and/or topical treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Reduced Intensity Regimen</title>
          <description>Alemtuzumab (Campath-IH) IV 3mg test dose on Day -20 followed by daily dose of 10mg/dose on Day -19 to Day -17 for patients &lt;10yrs or a daily dose of 15mg/dose on Day -19 to Day -17 for patients &gt; 10yrs. Fludarabine 35mg/m2 daily for 4 days on Day -7 to Day -4. Melphalan 70mg/m2 daily for 2 days on Day -3 and Day -2. Day -1 Cyclosporine OR Tacrolimus along with Mycophenolate Mofetil as a graft vs host disease prophylaxis. Day 0 the HLA matched or mismatched Hematopoietic Stem Cells from either the related or unrelated donor will be infused.&#xD;
alemtuzumab (Campath IH): Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17&#xD;
Fludarabine: Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.&#xD;
Melphalan: Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.&#xD;
Cyclosporine: Immunosuppressant to prevent graft vs host disease is given on Day -1&#xD;
Mycophenolate mofetil: Immunosuppressant to prevent graft vs host</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Graft vs Host Disease</sub_title>
                <description>22 participants experienced various grades of graft vs host disease (GVHD), inclusive of skin &amp; gut (acute and chronic). Of the 22, 2 participants expired from complication of graft vs host disease and 1 participant expired from a septic episode.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Grade I-II Graft vs Host Disease</sub_title>
                <description>13 patients experienced adverse event of Grade I-II graft vs host disease, and responded to oral and/or topical treatment.</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="29"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Indira Sahdev, MD</name_or_title>
      <organization>Northwell Health System Cohen Children's Medical Center of NY</organization>
      <phone>7184703460</phone>
      <email>isahdev@northwell.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

